Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 20, 2026

The Next Palantir Is Already Being Built, You Just Can’t Buy It Yet: 3 AI Companies to Watch in 2026

View original at finance.yahoo.com
The Next Palantir Is Already Being Built, You Just Can’t Buy It Yet: 3 AI Companies to Watch in 2026 While Palantir Technologies (PLTR) trades near all-time highs at premium multiples, a new generation of enterprise AI platforms is scaling rapidly, and may offer investors a more attractive entry point into the same tri…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Palantir's moat rests on three pillars: deeply embedded enterprise software that is difficult to replace, a government and defense franchise with high barriers to entry, and an AI platform that transforms data into operational decision-making

    60% confidence

  • Palantir just delivered what many investors viewed as one of the strongest recent earnings reports in enterprise software

    60% confidence

  • Databricks provides core data and AI infrastructure for a significant portion of large enterprises, including a majority of the Fortune 500

    60% confidence

  • The question for investors is not whether enterprise AI is real, it is. The question is whether Palantir at current multiples is the most efficient way to own that trend

    60% confidence

  • The question for investors is not whether enterprise AI is real, it is. The question is whether Palantir at current multiples is the most efficient way to own that trend.

    60% confidence

  • Palantir is an n of 1, meaning it is unique and without comparable peers

    60% confidence

  • Palantir is an n of 1

    60% confidence

  • Databricks provides core data and AI infrastructure for a significant portion of large enterprises, including a majority of the Fortune 500

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com